Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02314052 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02314052 is a Phase 1 study that was terminated before completion, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 21 participants.
The verdict
NCT02314052, a Phase 1 study, was terminated before completion, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematologic and solid tumor malignancies. In this study the Sponsor proposes to study DCR-MYC and its ability to inhibit MYC and thereby inhibit cancer cell growth.
Interventions
- DRUG DCR-MYC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-01-27 |
| Est. Completion | 2016-10-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02314052
The ClinicalTrials.gov registry entry for NCT02314052 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCR-MYC is the first listed.
NCT02314052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02314052 about?
NCT02314052 is a clinical study titled "Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma". The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene MYC. MYC oncogene activation is important to the growth of many hematolo...
What is the current status of trial NCT02314052?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-01-27. Estimated completion is 2016-10-11.
What interventions are being tested in trial NCT02314052?
The interventions under investigation include: DCR-MYC (DRUG).
Who is sponsoring clinical trial NCT02314052?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.